TIL therapy · cell therapy
lifileucel
0 active trials, targeting tumour-infiltrating lymphocytes. Not approved for any biomarker on marked.bio yet.
Also known as LN-144, Amtagvi.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| BRAF V600E | 0 | 1 | – |
Trials
0 of 1 trials shown
-
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
Patients who have been shown to be BRAF mutation positive (V600), but have not received prior systemic therapy with a BRAF inhibitor alone…
BRAF V600EMetastatic Melanoma
No trials match these filters.